Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been assigned a $8.00 price target by equities research analysts at Piper Jaffray Companies in a note issued to investors on Thursday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would suggest a potential downside of 5.33% from the stock’s current price.

SGMO has been the topic of several other research reports. Wedbush reissued a “neutral” rating and issued a $4.00 target price (down previously from $6.00) on shares of Sangamo Therapeutics in a report on Tuesday, May 16th. ValuEngine raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. BidaskClub lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $17.00 target price on shares of Sangamo Therapeutics in a report on Thursday, June 22nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $9.67.

Sangamo Therapeutics (NASDAQ SGMO) opened at 8.45 on Thursday. The firm’s 50-day moving average price is $9.01 and its 200 day moving average price is $6.10. Sangamo Therapeutics has a 12-month low of $2.65 and a 12-month high of $10.50. The stock’s market capitalization is $607.88 million.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.03. The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $4.14 million. Sangamo Therapeutics had a negative return on equity of 50.76% and a negative net margin of 380.44%. Sangamo Therapeutics’s revenue for the quarter was down 12.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.23) earnings per share. On average, equities analysts anticipate that Sangamo Therapeutics will post ($0.93) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/sangamo-therapeutics-inc-nasdaqsgmo-given-a-8-00-price-target-by-piper-jaffray-companies-analysts/1468526.html.

In related news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Friday, July 14th. The stock was sold at an average price of $10.00, for a total value of $150,000.00. Following the transaction, the vice president now owns 35,517 shares of the company’s stock, valued at $355,170. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 19,639 shares of company stock worth $184,765 in the last three months. 8.10% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the company. Swiss National Bank raised its position in shares of Sangamo Therapeutics by 26.4% in the second quarter. Swiss National Bank now owns 143,560 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 30,000 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Sangamo Therapeutics by 6.8% in the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares during the last quarter. Federated Investors Inc. PA purchased a new position in shares of Sangamo Therapeutics during the second quarter valued at about $1,304,000. Marshall Wace LLP purchased a new position in shares of Sangamo Therapeutics during the second quarter valued at about $507,000. Finally, Blair William & Co. IL raised its position in shares of Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares during the last quarter. 58.25% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.